Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma

X
Trial Profile

Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Pemetrexed (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms PrE0505
  • Most Recent Events

    • 29 Jun 2023 Status changed from active, no longer recruiting to completed.
    • 14 Sep 2021 Results of whole exome sequencing analysis assessing genomic and immune cell response to chemo-immunotherapy in malignant pleural mesothelioma patients presented at the 2021 World Conference on Lung Cancer
    • 11 Mar 2021 Time frame of primary endpoint changed from 72 to 32 months.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top